• contact
  • home
  • about
    • our history
    • management
    • board of directors
    • advisors
  • approach
  • pipeline
  • news & insights
    • presentations
    • press releases
    • references (PRL-02)
    • references (CGS-200-5)
  • careers
  • contact
  • Menu
  • newsworthy &
    insightful

    Stay updated and informed about all things Propella.

Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer

/in press releases /by george

Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-02-23 16:22:522021-09-09 15:19:57Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer

Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17, 2022; San Francisco, CA): Abiraterone decanoate (AD) – Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model

/in presentations /by george

Propella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA on February 11, 2021.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-02-22 11:33:212022-09-12 12:36:49Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17, 2022; San Francisco, CA): Abiraterone decanoate (AD) - Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model

Presentation (Webinar, February 9, 2021): Capsaicin – The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target

/in presentations /by george

Propella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-02-20 00:37:592022-09-12 12:39:53Presentation (Webinar, February 9, 2021): Capsaicin - The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target

Presentation at the 13th Annual Pain Therapeutics Summit (September 23, 2019; Washington, DC): A phase 2 double-blind clinical trial (VZU00025) to examine the tolerability, safety and effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on osteoarthritis knee pain (OAKP)

/in presentations /by george

Propella Therapeutics, Inc. presented the results of its completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 13th Annual Pain Therapeutics Summit in Washington, DC on September 23, 2019.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-01-15 01:30:302022-09-12 17:15:57Presentation at the 13th Annual Pain Therapeutics Summit (September 23, 2019; Washington, DC): A phase 2 double-blind clinical trial (VZU00025) to examine the tolerability, safety and effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on osteoarthritis knee pain (OAKP)

Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study

/in references (CGS-200-5) /by george
Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-01-14 15:57:112021-09-09 15:20:20Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study

Treatment of Arthritis with Topical Capsaicin: A Double-Blind Trial

/in references (CGS-200-5) /by george
Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-01-14 15:54:092021-09-09 15:20:26Treatment of Arthritis with Topical Capsaicin: A Double-Blind Trial
Page 3 of 7‹12345›»

categories

  • presentations
  • press releases
  • references (CGS-200-5)
  • references (PRL-02)
  • home
  • about
  • approach
  • pipeline
  • news & insights
  • careers
  • contact
© 2020-2023 Propella Therapeutics, Inc. / all rights reserved
  • privacy policy
  • terms of use
  • copyright policy
Scroll to top